Recent research presented at the American Society of Clinical Oncology (ASCO GU 2025) highlights a novel therapeutic target for treatment-induced neuroendocrine prostate cancer (t-NEPC), a highly aggressive form of prostate cancer that often arises following standard treatments. The study focuses on inhibiting NSD2, an epigenetic regulator implicated in cancer progression.

The identification of NSD2 as a potential therapeutic target opens new avenues for treating t-NEPC. A selective NSD2 inhibitor KTX1001 that is currently undergoing clinical evaluation in multiple myeloma (NCT05651932) has given great results in vitro and in vivo against t-NEPC.

Further research is necessary to validate these findings and develop effective NSD2 inhibitors for clinical use.

This development underscores the importance of exploring epigenetic mechanisms in cancer therapy and offers hope for improved treatments for patients with aggressive prostate cancer subtypes.

Source.